B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.